# Long-term prognostic value of microvascular obstruction by cardiac magnetic resonance in ST-segment elevation myocardial infarction

**Authors:** Raquel P. Amier, Casper W. H. Beijnink, José F. Rodriguez Palomares, Martijn W. Smulders, Gonzalo Pizarro Sánchez, Rodrigo Fernández-Jiménez, Filipa X. Valente, Albert C. van Rossum, Niels van Royen, Borja Ibañez, Robin Nijveldt

PMC · DOI: 10.1371/journal.pone.0344442 · 2026-03-06

## TL;DR

This study shows that microvascular obstruction detected by MRI after heart attacks is linked to higher death risk for up to six years, but not beyond.

## Contribution

The study provides long-term (up to 6 years) prognostic data on microvascular obstruction in STEMI patients using cardiac MRI.

## Key findings

- MVO was associated with a 2.23-fold higher risk of all-cause mortality up to six years post-STEMI.
- The association between MVO and mortality dissipated after six years of follow-up.
- MVO was not significantly linked to combined mortality and ischemic events before or after six years.

## Abstract

Microvascular obstruction (MVO) portends a higher risk of remodelling and adverse events following ST-segment elevation myocardial infarction (STEMI). However, data regarding the implications of MVO in STEMI beyond five years of follow-up are scarce.

This is a pooled analysis of three observational studies including 876 prospectively enrolled reperfused first STEMI patients, who underwent cardiac magnetic resonance imaging with late gadolinium enhancement (LGE), between 2003–2019. Median follow-up duration was 6.3 (IQR 3.6–9.3) years. The primary outcome was all-cause mortality. The secondary outcome was a combined endpoint of all-cause mortality and recurrent ischemic events (i.e., myocardial infarction or stroke). We performed Cox regression analyses with a time-dependent covariate.

The study population consisted of 876 patients, mean age 59 years ± 12, 720 men (82%). MVO was present in 499 patients (58%). The presence of MVO was independently associated with all-cause mortality up to six years post-STEMI (Hazard Ratio [HR] 2.23, 95% CI 1.09–4.57, p = 0.029), but not after six years post-STEMI (HR 0.98, 95% CI 0.45–2.12, p = 0.958). Presence of MVO was not significantly associated with a combined endpoint of all-cause mortality and recurrent ischemic events before or after six years of follow-up (HR 1.27, 95% CI 0.81–1.99, p = 0.294 and HR 0.68, 95% CI 0.35–1.31, p = 0.244, respectively).

In STEMI patients, the presence of MVO by cardiac magnetic resonance imaging is associated with a more than two-fold higher risk of all-cause mortality up to six years after the index event. This relation seems to dissipate beyond this time period.

## Linked entities

- **Diseases:** myocardial infarction (MONDO:0005068), ST-segment elevation myocardial infarction (MONDO:0041656)

## Full-text entities

- **Diseases:** cardiac remodelling (MESH:D020257), Heart failure (MESH:D006333), Infarct (MESH:D007238), CMR (MESH:C564543), hypertension (MESH:D006973), Mortality (MESH:D003643), atherosclerosis disease (MESH:D050197), MVO (MESH:D017566), MI (MESH:D009203), cardiovascular (MESH:D002318), stroke (MESH:D020521), sudden cardiac death (MESH:D016757), ST-segment elevation (MESH:D000072657), ischemic (MESH:D002545), diabetes mellitus (MESH:D003920)
- **Chemicals:** Gadolinium (MESH:D005682), metoprolol (MESH:D008790), MVO (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965695/full.md

---
Source: https://tomesphere.com/paper/PMC12965695